Codex DNA, Inc. (DNAY) |
|
2.16 0.05 (2.37%)
|
08-19 00:43 |
|
Open: |
2.14 |
Pre. Close: |
2.11 |
|
High:
|
2.195 |
Low:
|
2.082 |
|
Volume:
|
71,942 |
Market Cap:
|
64(M) |
|
|
|
|
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.23 - 2.25 |
2.25 - 2.26 |
|
Low:
|
2.03 - 2.05 |
2.05 - 2.07 |
|
Close:
|
2.08 - 2.11 |
2.11 - 2.13 |
|
Technical analysis |
as of: 2022-08-18 3:52:05 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 3.03 One year: 3.54 |
| Support: |
Support1: 2.02 Support2: 1.66 |
| Resistance: |
Resistance1: 2.59 Resistance2: 3.03 |
| Pivot: |
2.14 |
| Moving Average: |
MA(5): 2.25  MA(20): 2.08
MA(100): 3.19 MA(250): 6.76 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 46.3 %D(3): 55.8 |
| RSI: |
RSI(14): 50.7 |
| 52-week: |
High: 14.98 Low: 1.66 |
| Average Vol(K): |
3-Month: 627 (K) 10-Days: 478 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNAY ] has closed below upper band by 45.8%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Mon, 15 Aug 2022
Is Codex DNA Inc (DNAY) Stock About to Get Hot Monday? - InvestorsObserver
Wed, 10 Aug 2022
BLUE, INVZ and AQST are among pre market gainers - Seeking Alpha
Wed, 10 Aug 2022
Premarket Mover: Codex DNA Inc (DNAY) Up 5.56% - InvestorsObserver
Tue, 02 Aug 2022
Is Codex DNA Inc (DNAY) Stock Worth a Buy Tuesday? - InvestorsObserver
Tue, 26 Jul 2022
Codex DNA Inc (DNAY) Down 2.13% in Premarket Trading - InvestorsObserver
Thu, 30 Jun 2022
Pre-market Movers: ASPN, SCWO, HYPR, DNAY, XCUR… - RTTNews
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
29 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
37.2 (%) |
|
% Held by Institutions
|
59.6 (%) |
|
Shares Short
|
337 (K) |
|
Shares Short P.Month
|
798 (K) |
Stock Financials |
|
EPS
|
-1.85 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.66 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-290.4 |
|
Return on Assets (ttm)
|
-36.6 |
|
Return on Equity (ttm)
|
-106.1 |
|
Qtrly Rev. Growth
|
142.1 |
|
Gross Profit (p.s.)
|
0.14 |
|
Sales Per Share
|
0.48 |
|
EBITDA (p.s.)
|
-1.39 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-37 (M) |
|
Levered Free Cash Flow
|
-25 (M) |
Stock Valuations |
|
PE Ratio
|
-1.18 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.81 |
|
Price to Sales
|
4.44 |
|
Price to Cash Flow
|
-1.72 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
